Article Data

  • Views 852
  • Dowloads 134


Open Access

Radiotherapy and gynaecological cancers during the pandemic: the role of hematologic toxicity

  • Giuseppe Carlo Iorio1,*,
  • Valeria Chiofalo1
  • Umberto Ricardi1

1Department of Oncology, University of Torino, 10125 Torino, Italy

DOI: 10.22514/ejgo.2023.092 Vol.44,Issue 6,December 2023 pp.1-3

Submitted: 23 March 2023 Accepted: 30 May 2023

Published: 15 December 2023

*Corresponding Author(s): Giuseppe Carlo Iorio E-mail:


The COVID-19 pandemic has killed more than 6.8 million people worldwide since late 2019. A hyperinflammatory condition depending on interleukin-6 (IL-6) rise and hypercytokinemia have been linked with fatality rates. This condition can lead to lymphocyte-deficiency. Lymphopenia came up as a major prognosticator of severe infection cases. Cancer therapies can induce lymphopenia due to reservoir lymphoid organ damage. The principal cause of hematologic toxicity (HT) is usually chemotherapy (ChT). Nonetheless, also radiotherapy contributes to hematologic cell lines impairment, impacting mainly on lymphocytes. Radiation-induced lymphopenia (RIL) has been linked to unfavorable outcomes in various solid tumors. In pelvic cancers, bone marrow (BM) dose-volume metrics have been related to HT occurrence, particularly Gynaecological Cancers. The present times offer an unprecedented opportunity to broadly embrace treatment strategies, as BM sparing (BMS), that avoid reservoir lymphoid organs’ suppression and the potential subsequent RIL.


COVID-19; Lymphopenia; Cancer care; Radiotherapy

Cite and Share

Giuseppe Carlo Iorio,Valeria Chiofalo,Umberto Ricardi. Radiotherapy and gynaecological cancers during the pandemic: the role of hematologic toxicity. European Journal of Gynaecological Oncology. 2023. 44(6);1-3.


[1] Johns Hopkins Coronavirus Resource Center. COVID-19 Map. 2023. Available at: (Accessed: 06 June 2023).

[2] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020; 395: 1033–1034.

[3] Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduction and Targeted Therapy. 2020; 5: 33.

[4] Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. International Journal of Infectious Diseases. 2020; 96: 131–135.

[5] Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. The Lancet Respiratory Medicine. 2020; 8: e24.

[6] Lambin P, Lieverse RIY, Eckert F, Marcus D, Oberije C, van der Wiel AMA, et al. Lymphocyte-sparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy. Seminars in Radiation Oncology. 2020; 30: 187–193.

[7] Iorio GC, Spieler BO, Ricardi U, Dal Pra A. The impact of pelvic nodal radiotherapy on hematologic toxicity: a systematic review with focus on leukopenia, lymphopenia and future perspectives in prostate cancer treatment. Critical Reviews in Oncology/Hematology. 2021; 168: 103497.

[8] Trowell OA. The sensitivity of lymphocytes to ionising radiation. The Journal of Pathology and Bacteriology. 1952; 64: 687–704.

[9] Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiation Research. 1990; 123: 224–227.

[10] Mussano F, Lee KJ, Zuk P, Tran L, Cacalano NA, Jewett A, et al. Differential effect of ionizing radiation exposure on multipotent and differentiation restricted bone marrow mesenchymal stem cells. Journal of Cellular Biochemistry. 2010; 111: 322–332.

[11] Belka C, Marini P, Budach W, Schulze-Osthoff K, Lang F, Gulbins E, et al. Radiation-induced apoptosis in human lymphocytes and lymphoma cells critically relies on the up-regulation of CD95/Fas/APO-1 ligand. Radiation Research. 1998; 149: 588–595.

[12] Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004; 100: 2281–2291.

[13] Gao K, Chen Y, Wei L, Li S, Jin X, Cong C, et al. Inhibitory effect of mesenchymal stem cells on lymphocyte proliferation. Cell Biochemistry and Function. 2008; 26: 900–907.

[14] Iorio GC, Ricardi U, Franco P. The importance of IL-6 blockade beyond the COVID-19 pandemic: consideration for cancer care. Radiotherapy and Oncology. 2020; 151: 24–25.

[15] Iorio GC, Ricardi U, Dal Pra A. Radiation-induced lymphopenia beyond the COVID-19 pandemic. Frontiers in Oncology. 2020; 10: 617302.

[16] Iorio GC, Ammendolia A, Marotta N, Ricardi U, de Sire A. A bond between rheumatic diseases and cancer in the elderly: the interleukin-6 pathway. International Journal of Rheumatic Diseases. 2021; 24: 1317–1320.

[17] Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology. 2018; 15: 234–248.

[18] Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, et al. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cellular Immunology. 2021; 359: 104254.

[19] Matsuoka Y, Nakayama H, Yoshida R, Hirosue A, Nagata M, Tanaka T, et al. IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma. British Journal of Cancer. 2016; 115: 1234–1244.

[20] TRIPPLE-R: phase 2 study in pretreated patients with advanced pancreatic cancer to assess efficacy of ipilimumab, nivolumab and tocilizumab in combination with radiation. Available at: (Accessed: 06 January 2022).

[21] Abdel-Wahab N, Montazari E, Spillson C, Bentebibel S E, Awiwi M, Elsayes K M, et al. Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma. 2022. Available at: (Accessed: 02 June 2022).

[22] Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma. Available at: (Accessed: 06 June 2023).

[23] Han X, Yang Q, Zhang J, Cao J. Correlation between changes in the number of peripheral blood lymphocytes and survival rate in patients with cervical cancer after radio-chemotherapy. Cancer/RadiothéRapie. 2021; 25: 72–76.

[24] Albuquerque K, Giangreco D, Morrison C, Siddiqui M, Sinacore J, Potkul R, et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow—sparing pelvic IMRT. International Journal of Radiation Oncology, Biology, Physics. 2011; 79: 1043–1047.

[25] Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. International Journal of Radiation Oncology, Biology, Physics. 2013; 86: 83–90.

[26] Mell LK, Sirák I, Wei L, Tarnawski R, Mahantshetty U, Yashar CM, et al. Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB–IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2). International Journal of Radiation Oncology, Biology, Physics. 2017; 97: 536–545.

[27] McGuire SM, Bhatia SK, Sun W, Jacobson GM, Menda Y, Ponto LL, et al. Using [18F]fluorothymidine imaged with positron emission tomography to quantify and reduce hematologic toxicity due to chemoradiation therapy for pelvic cancer patients. International Journal of Radiation Oncology, Biology, Physics. 2016; 96: 228–239.

[28] Dinges E, Felderman N, McGuire S, Gross B, Bhatia S, Mott S, et al. Bone marrow sparing in intensity modulated proton therapy for cervical cancer: efficacy and robustness under range and setup uncertainties. Radiotherapy and Oncology. 2015; 115: 373–378.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time